64.25USD-0.53%Mkt Cap: 5.67B USDP/E: —Last update: 2026-05-22
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cre…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap5.67B USD
Enterprise Value4.63B USD
Revenue (TTM)5.07M USD
Gross Profit-607.00K USD
Net Income (TTM)-161.00M USD
Revenue/Share0.0640 USD
Last Price64.25 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees142
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-23.24
PEG—
EV/EBITDA-21.76
EV/Revenue912.71
P/S1123.45
P/B5.21
EPS (TTM)-2.34
EPS (Forward)-2.78
52W Range
23.6578% of range75.50
52W High75.50 USD
52W Low23.65 USD
Profitability
Gross Margin-15.02%
Oper. Margin-6130.10%
EBITDA Margin0.00%
Profit Margin-3985.02%
ROE-21.39%
ROA-20.34%
Growth
Revenue Growth1982.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-132.35M USD
CapEx (TTM)134.00K USD
FCF Margin-2088.16%
FCF Yield-1.87%
Net Debt-1.07B USD
Net Debt/EBITDA5.02
Balance Sheet
Debt/Equity0.01
Current Ratio31.30
Quick Ratio30.60
Book Value/Sh12.40 USD
Cash/Share12.20 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)90.29 USD
Target Range80.00 USD – 108.00 USD
# Analysts14
Ownership
Shares Out.88.20M
Float65.82M
Insiders0.23%
Institutions108.78%
Short Interest
Short Ratio8.2d
Short % Float10.67%
Short % Out.10.48%
Shares Short9.22M
Short (prev mo.)10.54M
Technical
SMA 5067.28 (-4.5%)
SMA 20048.76 (+31.8%)
Beta0.42
S&P 52W Chg28.31%
Avg Vol (30d)955.25K
Avg Vol (10d)1.03M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—